MetaCap

CRISPR Therapeutics AG (CRSP)

NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

39.10+0.17 (+0.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRSP stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.73
52-week range
38.15 – 63.45
Day range
38.18 – 40.17
Volume / Avg
3.32M / 1.74M
Beta
—

52-week range

$38.15$63.45

CRSP stock today

Shares of CRISPR Therapeutics (CRSP) finished higher on Nov 20 at $39.10, a gain of 0.44% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, CRSP sits near the bottom of its 52-week range of $38.15 to $63.45: 38.4% below the high, set on Jul 6, 2026 and 2.5% above the low. CRSP is down 25.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.2%.

CRISPR Therapeutics has posted a net loss over the last twelve months (EPS of -$4.73), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About CRISPR Therapeutics

Company profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Samarth Kulkarni Ph.D.
Headquarters
Zug
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, CRISPR Therapeutics generated $3.5 million in revenue, down 90.6% from fiscal 2024, its first annual decline since 2024. CRISPR Therapeutics reported a net loss of $581.6 million, compared with a loss of $366.3 million a year earlier. Operating margin was -18933.6%.

CRISPR Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$3.51M$37.31M$371.21M$1.20M$914.96M
Growth-90.59%-89.95%+30885.48%-99.87%+127154.94%
Net income$-581.60M$-366.25M$-153.61M$-650.17M$377.66M
EPS (diluted)$-6.47$-4.34$-1.94$-8.36$4.70

Analyst forecast

Forecast

Consensus (23 analysts)

buy

Avg. price target

$85.42+118.47%

  • Strong buy 4
  • Buy 9
  • Hold 10
  • Sell 0
  • Strong sell 0

Target range

Low $44.00High $291.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-1.15 vs $-1.06
Surprise
-8.49%

CRSP news

All CRSP news

CRISPR Therapeutics peers

Health Care sector
CRSP peer companies
CompanyPrice% ChgMarket capCompare
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs CRSP
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs CRSP
IOVAIovance Biotherapeutics Inc.6.90-5.61%$3.19Bvs CRSP
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs CRSP
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs CRSP
VCELVericel Corporation57.52-1.27%$2.94Bvs CRSP
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs CRSP
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs CRSP

Indexes, lists and sector

CRISPR Therapeutics stock FAQ

What is CRISPR Therapeutics's stock price today?

CRSP last traded at $39.10 as of Nov 20, 4:00 PM EST, up 0.44% on the day. Prices are delayed at least 15 minutes.

Who is CRISPR Therapeutics's CEO?

Dr. Samarth Kulkarni Ph.D. is the chief executive officer of CRISPR Therapeutics AG.

What is the CRSP 52-week high?

The 52-week high for CRSP is $63.45 and the 52-week low is $38.15. The stock is currently 38.4% below its high.

Compare CRSP